Baricitinib for Respiratory Injury in Patients With Intracerebral Hemorrhage

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

August 18, 2025

Study Completion Date

August 18, 2025

Conditions
Intracerebral HemorrhageAcute Lung Injury(ALI)
Interventions
DRUG

Baritinib

Participants will receive additional baritinib administration with 4-mg dosage once daily (QD) for consecutive 14 days after randomization (adjusted dosage of 2-mg QD for participants with eGFR between 30-60 mL/min/1.73m\^2).

Trial Locations (6)

341000

First Affiliated Hospital of Gannan Medical University, Ganzhou

Ganzhou People's Hospital, Ganzhou

350003

First Affiliated Hospital of Fujian Medical University, Fuzhou

400038

The Southwest Hospital of Army Medical University, Chongqing

Unknown

Liaocheng People's Hospital, Liaocheng Brain Hospital, Liaocheng

Tianjin Huanhu Hospital, Tianjin

All Listed Sponsors
collaborator

Fujian Medical University

OTHER

collaborator

Tianjin Medical University General Hospital

OTHER

lead

De-zhi Kang

OTHER

NCT06737705 - Baricitinib for Respiratory Injury in Patients With Intracerebral Hemorrhage | Biotech Hunter | Biotech Hunter